Shatavari: The Ayurvedic Root Western Research Only Just Caught Up With
Ashwagandha crossed over. Turmeric crossed over. Ashwagandha's sister herb — the one Ayurvedic practitioners actually reserved for women — spent those decades almost invisible in Western supplement aisles.
Then 2025 happened. Three randomised, double-blind, placebo-controlled trials of shatavari in perimenopausal and menopausal women published inside twelve months, in Frontiers in Reproductive Health, the International Journal of Women's Health, and the Journal of the American Nutrition Association.
That's an unusual amount of clinical attention for a botanical most people can't pronounce. Here's what the studies actually measured, and what they didn't.
Key takeaways
- Shatavari (Asparagus racemosus) is the herb Ayurveda designated as its primary women's tonic — documented in the Charaka Samhita as support for female vitality across every life stage.
- Its active compounds are steroidal saponins called shatavarins, which interact with estrogen receptor pathways. Interact with, not imitate.
- In a 2025 three-arm RCT, 300 mg daily for 8 weeks improved Menopause Rating Scale scores by about 13 points, versus 3.26 for placebo (p < 0.0001).
- Hormone levels didn't move. Estradiol, FSH, LH and testosterone showed no significant between-group differences at week 8.
- The trials used standardised extracts — typically >10% shatavarins. As with every botanical, the extract form is as important as the milligram count.
What shatavari is
Asparagus racemosus is a climbing plant native to India, Sri Lanka and the Himalayan foothills — a genuine relative of the asparagus on your dinner plate, though you wouldn't want to eat it. The medicinal part is a cluster of tuberous roots.
The Sanskrit name is the reason most people remember it: shatavari, roughly "she who possesses a hundred husbands." Read it as vitality rather than as arithmetic. It reflects the herb's traditional reputation for supporting women's energy, resilience and reproductive health through every phase of life — menstruation, fertility, postpartum, and the menopause transition.
Ayurveda classifies it as a rasayana: a rejuvenative tonic taken over long periods for resilience rather than as an acute remedy for a symptom. That framing turns out to match how the modern trials were designed — 8 to 12 weeks of daily use, measuring a composite symptom score rather than one dramatic endpoint.
How it's thought to work
Shatavari roots contain shatavarins I–IV, steroidal saponins that bind estrogen receptors.
The distinction that matters, and that gets flattened in most supplement copy: a phytoestrogen is not estrogen. It's a plant compound with enough structural similarity to dock at the same receptor, but with far weaker activity than the hormone itself. Think of a key that fits the lock and turns it partway.
This is why the hormone data from the 2025 trial is the most quietly significant finding in the whole file. If shatavari were acting as an estrogen, you would expect serum estradiol, FSH and LH to shift. They didn't. Symptoms improved; hormone levels stayed put.
Whatever shatavari is doing, it appears to be doing it through receptor signalling rather than by adding hormone to the system.
What the 2025 research found
The three-arm trial
The headline study is Ademola, Ajgaonkar, Debnath, Debnath and Langade (2025), Frontiers in Reproductive Health 7:1654503, PMID 41394012.
Design: randomised, double-blind, three-arm, placebo-controlled. 135 women aged 45–65, 45 per arm, 8 weeks:
| Arm | Daily dose |
|---|---|
| Shatavari alone | 300 mg shatavari root extract |
| Combination | 250 mg ashwagandha + 300 mg shatavari |
| Placebo | 300 mg placebo |
Primary outcome was the Menopause Rating Scale — an 11-item validated questionnaire covering hot flushes, sleep, mood, joint discomfort, irritability and more.
Results at week 8:
| Arm | MRS change |
|---|---|
| Ashwagandha + shatavari | −13.08 |
| Shatavari alone | −13.07 |
| Placebo | −3.26 |
Both active arms beat placebo at p < 0.0001. The trial also reported significant between-group improvements in mood (p = 0.008) and esteem-related affect (p = 0.025).
Hormones at week 8 — the part worth reading twice:
| Marker | Combo | Shatavari | Placebo | p |
|---|---|---|---|---|
| Estradiol (pg/ml) | 45.88 | 45.09 | 44.45 | 0.894 |
| FSH (IU/L) | 20.85 | 19.58 | 18.90 | 0.660 |
| LH | — | — | — | 0.888 |
| Testosterone | — | — | — | 0.619 |
No significant differences. Symptom scores moved; hormone levels didn't.
Safety: four participants across 135 reported mild adverse events — loose stools and dizziness in the combination arm, nausea in the shatavari arm, headache on placebo.
The other two
An 8-week study of 300 mg once daily in women with perimenopausal symptoms was published in the International Journal of Women's Health in November 2025. Separately, a randomised, double-blind, placebo-controlled trial in 50 perimenopausal women aged 40–50 with mild-to- moderate climacteric symptoms, published in the Journal of the American Nutrition Association in May 2025, reported reductions in vasomotor symptoms alongside changes in hormonal and menstrual-health measures.
Three independent trials, one consistent direction of effect. That's a better evidence base than most botanicals in this category — and still a young one.
The limits, stated plainly
The trials are small. 135, 50, and similar. These are respectable phase-appropriate studies, not the multi-thousand-participant trials behind pharmaceutical approvals.
Eight weeks is eight weeks. Nobody has published a two-year shatavari trial in menopausal women.
Several trials come from research groups with industry connections, which is normal in botanical research and still worth knowing.
Extract form is doing quiet work. The trials used extracts standardised to a stated shatavarin content, commonly >10%. A generic "10:1 extract" at the same milligram figure is not a like-for-like substitute — that ratio describes how much raw root went into the extraction, not how much active compound came out.
Frequently asked questions
Is shatavari a hormone? No. It contains plant compounds that interact with estrogen receptors. In the 2025 trial, estradiol, FSH, LH and testosterone were unchanged after 8 weeks.
Can I take shatavari if I have an estrogen-sensitive condition? Speak to your doctor first. Because shatavari acts on estrogen receptor pathways, anyone with a history of estrogen-sensitive cancer, endometriosis or fibroids should get individual medical advice before using it.
What dose was studied? 300 mg daily of a standardised root extract, for 8 weeks, in the trials above.
Shatavari or ashwagandha? Different jobs. Ashwagandha's evidence sits around cortisol and the stress axis; shatavari's sits around menopausal symptom scores and hormonal signalling. In the three-arm trial, the combination and shatavari alone landed in effectively the same place on the MRS — the combination did not outperform shatavari on that measure. More on ashwagandha here.
How long until anything happens? Trials measured at 4 and 8 weeks, with differences from placebo visible by week 4.
Can I take it while breastfeeding? Shatavari has traditional use as a galactagogue, but traditional use is not clinical evidence. Ask your healthcare provider.
Where shatavari sits in AROSE Happy Harmony
Most hormone gummies lead with ashwagandha because it's familiar. AROSE Happy Harmony was built around shatavari because that's the herb Ayurveda actually pointed at women — and now the one with 2025 randomised trials behind it.
Each 3-gummy serving contains 250 mg shatavari root extract (10:1) alongside 250 mg ashwagandha, 200 mg maca extract, 150 mg sage, 150 mg fennel, 100 mg chamomile, 75 mg chaste tree berry, 28 mg standardised saffron and vitamin B6.
Two disclosures, because you should be able to do this maths yourself:
Our shatavari is 250 mg; the trials used 300 mg. That's about 17% under the studied dose.
Ours is a 10:1 extract, not a shatavarin-standardised one. Same herb, different specification from the trial material. Standardising the lead botanicals is the next change on our formulation roadmap.
We publish those gaps for the same reason we publish the doses: a label you can check against a PubMed abstract is the only kind worth printing. Happy Harmony is formulated to support hormone balance, a healthy stress response, mood and restful sleep.* It contains no hormones.
* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Educational content, not medical advice. Fennel, chaste tree berry and sage act on estrogen pathways — not for use in pregnancy, while breastfeeding, or with an estrogen-sensitive condition without medical guidance.
